My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
UCO Bank gains after allotting preferential shares to LIC
Nov 30,2016

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the S&P BSE Sensex was up 104.27 points or 0.4% at 26,498.28.

On the BSE, 63,000 shares were traded on the counter so far as against the average daily volumes of 2.22 lakh shares in the past one quarter. The stock had hit a high of Rs 34.30 and a low of Rs 33.85 so far during the day. The stock had hit a 52-week high of Rs 50.15 on 1 December 2015. The stock had hit a 52-week low of Rs 27.80 on 15 February 2016. The stock had outperformed the market over the past one month till 29 November 2016, declining 3.31% compared with the Sensexs 5.54% fall. The scrip had, however, underperformed the market in past one quarter, sliding 16.52% as against the Sensexs 5.41% fall.

The mid-cap bank has equity capital of Rs 1488.03 crore. Face value per share is Rs 10.

The shares issued to Life Insurance Corporation of India (LIC) will be under lock-in for a period of one year from the date of trading from the stock exchanges. LIC owned 11.88% stake in UCO Bank end September 2016.

UCO Bank reported net loss of Rs 384.83 crore in Q2 September 2016, compared with net profit of Rs 156.20 crore in Q2 September 2015.

The Government of India held 77.54% stake in UCO Bank end September 2016.

Powered by Capital Market - Live News

Eros International advances on fund raising plans
Nov 30,2016

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the BSE Sensex was up 115.17 points, or 0.44%, to 26,509.66.

On the BSE, 7,267 shares were traded so far in the counter, compared with average daily volume of 43,372 shares in the past one quarter. The stock had hit a high of Rs 174.90 and a low of Rs 170.10 so far during the day. The stock had hit a 52-week high of Rs 274 on 4 December 2015. The stock had hit a 52-week low of Rs 125.90 on 29 February 2016. The stock had underperformed the market over the past one month till 29 November 2016, falling 12.25% compared with 5.54% fall in the Sensex. The scrip had also underperformed the market in past one quarter, falling 21.39% as against Sensexs 5.41% decline.

The small-cap company has equity capital of Rs 93.71 crore. Face value per share is Rs 10.

Eros International Media said that the meeting of board of directors of the company will be held on 2 December 2016, to consider and approve the proposal to raise funds through issue and offer of secured/unsecured, redeemable, non convertible debentures on public/private placement basis, in one or more tranches, upto the limit as may be decided by the board.

On a consolidated basis, net profit of Eros International Media fell 32.9% to Rs 62.99 crore on 5.2% decline in net sales to Rs 478.79 crore in Q2 September 2016 over Q2 September 2015.

Eros International Media operates in the Indian film entertainment industry. It acquires, co-produces and distributes Indian films across all available formats such as cinema, television and digital new media.

Powered by Capital Market - Live News

HCC nudges higher on mulling preferential share allotment
Nov 30,2016

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the S&P BSE Sensex was up 131.10 points or 0.5% at 26,525.11.

On the BSE, 3.95 lakh shares were traded on the counter so far as against the average daily volumes of 28.59 lakh shares in the past one quarter. The stock had hit a high of Rs 34.70 and a low of Rs 34.25 so far during the day. The stock had hit a 52-week high of Rs 41.90 on 14 September 2016. The stock had hit a 52-week low of Rs 16.60 on 12 February 2016. The stock had underperformed the market over the past one month till 29 November 2016, declining 7.02% compared with the Sensexs 5.54% fall. The scrip had, however, outperformed the market in past one quarter, surging 46.96% as against the Sensexs 5.41% fall.

The small-cap company has equity capital of Rs 77.92 crore. Face value per share is Rs 1.

Hindustan Construction Companys (HCC) board at its proposed board meeting on 2 December 2016, would consider issue of equity shares representing 24.44% of the expanded capital and also optionally convertible debentures (OCDs) on preferential basis, to be allotted collectively to the individual lenders. In this context, the company plans to convene an extraordinary general meeting (EGM) for seeking shareholders approval.

HCCs net profit fell 42.8% to Rs 23.08 crore on 8.2% decline in net sales to Rs 759.03 crore in Q2 September 2016 over Q2 September 2015.

HCC is into infrastructure development in transportation, power and water segments.

Powered by Capital Market - Live News

Sarda Energy & Minerals spurts after restarting mining operations
Nov 30,2016

The announcement was made after trading hours yesterday, 30 November 2016.

Meanwhile, the BSE Sensex was up 92.11 points, or 0.35%, to 26,486.12.

On BSE, so far 59,000 shares were traded in the counter, compared with average daily volume of 86,198 shares in the past one quarter. The stock hit a high of Rs 256.65 and a low of Rs 235.50 so far during the day. The stock hit a 52-week high of Rs 296.60 on 1 November 2016. The stock hit a 52-week low of Rs 75.50 on 26 February 2016. The stock had underperformed the market over the past 30 days till 29 November 2016, falling 15.83% compared with the 5.50% decline in the Sensex. The scrip had, however, outperformed the market in past one quarter, rising 33.55% as against Sensexs 7.23% decline.

The small-cap company has equity capital of Rs 36.02 crore. Face value per share is Rs 10.

On 9 March 2016, Sarda Energy & Minerals announced temporary suspension of operation at its iron ore mine in Dongarbore (Chhattisgarh) after a naxalite attack on 7 March 2016, which caused death of one employee and damage of a few vehicles.

Net profit of Sarda Energy & Minerals rose 250.3% to Rs 12.54 crore on 2.7% decline in net sales to Rs 253 crore in Q2 September 2016 over Q2 September 2015.

Sarda Energy & Minerals (SEML) is one of the lowest cost producers of steel (sponge iron, billets, ingots, TMT bars) and one of the largest manufacturers and exporters of ferro alloys in India.

Powered by Capital Market - Live News

Vivimed Labs spurts after unit successfully completes USFDA inspection
Nov 30,2016

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the S&P BSE Sensex was up 78.36 points or 0.3% at 26,472.37.

On the BSE, 3.78 lakh shares were traded on the counter so far as against the average daily volumes of 2.89 lakh shares in the past one quarter. The stock had hit a high of Rs 107.40 and a low of Rs 102 so far during the day. The stock had hit a record high of Rs 121.15 on 4 October 2016. The stock had hit a 52-week low of Rs 68 on 9 August 2016. The stock had underperformed the market over the past one month till 29 November 2016, declining 13.97% compared with the Sensexs 5.54% fall. The scrip had, however, outperformed the market in past one quarter, advancing 24.63% as against the Sensexs 5.41% fall.

The large-cap company has equity capital of Rs 16.20 crore. Face value per share is Rs 2.

The audit was conducted during the last week of November and concluded on 28 November 2016. Furthermore, Vivimed obtained abbreviated new drug application (ANDA) approval for Metronidazole and same is commercialised. During November 2016, the company acquired ANDA of Zolpidem and the file transfer has successfully been completed. It is expected to be commercialised by Q4 March 2017.

Vivimed is on track of its filing targets and has successfully completed 3 ANDA filings during the current financial year and expect one more filing to be completed by Q4 March 2017. These products provide vertical integration with the in-house active pharmaceutical ingredients (APIs).

Santosh Varalwar, Managing Director of Vivimed Labs, said the company is on track with its filings pipeline which are expected to bear fruits when these products start to commercialise over the next 18-24 months.

On a consolidated basis, Vivimed Labs net profit rose 12.4% to Rs 26.85 crore on 11.5% decline in net sales to Rs 298.36 crore in Q2 September 2016 over Q2 September 2015.

Vivimed Labs is a niche specialty chemicals and pharmaceuticals company.

Powered by Capital Market - Live News

Lupin gains after receiving USFDA approval for Armodafinil tablets
Nov 30,2016

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the BSE Sensex was up 67.23 points, or 0.25%, to 26,461.24.

On BSE, so far 25,000 shares were traded in the counter, compared with average daily volume of 99,927 shares in the past one quarter. The stock hit a high of Rs 1,545.55 and a low of Rs 1,526.90 so far during the day. The stock hit a 52-week high of Rs 1,911.55 on 9 February 2016. The stock hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had outperformed the market over the past 30 days till 29 November 2016, falling 0.06% compared with the 5.50% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 2.25% as against Sensexs 7.23% decline.

The large-cap company has equity capital of Rs 90.27 crore. Face value per share is Rs 2.

Lupin announced that its US subsidiary Lupin Pharmaceuticals Inc (LPI) has received final approval from the United States Food and Drug Administration (USFDA) to market Armodafinil tablets 50mg, 150mg, 200mg and 250mg. LPI shall commence promoting the product in the US shortly. Lupins Armodafinil tablets are the AB rated generic equivalents of Cephalon, Incs Nuvigil tablets. Armodafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy or shift work disorder (SWD). Nuvigil tablets had annual US sales of $515.6 million as per IMS MAT September 2016 data.

Lupins consolidated net profit jumped 57.8% to Rs 662.19 crore on 31.9% rise in net sales to Rs 4211.18 crore in Q2 September 2016 over Q2 September 2015.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, central nervous system (CNS), GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Powered by Capital Market - Live News

Tata Power witnesses initial volatility post impressive Q2 numbers
Nov 30,2016

Meanwhile, the S&P BSE Sensex was up 70.19 points or 0.27% at 26,464.20.

On the BSE, 1.34 lakh shares were traded on the counter so far as against average daily volume of 4.82 lakh shares in the past one quarter. The stock had hit a high of Rs 72.75 and a low of Rs 71.05 so far during the day. The stock had hit a 52-week high of Rs 84.45 on 24 October 2016. The stock had hit a 52-week low of Rs 55 on 12 February 2016. The stock had underperformed the market over the past one month till 29 November 2016, declining 7.97% compared with the Sensexs 5.54% fall. The scrip had, however, outperformed the market in past one quarter, sliding 4.87% as against the Sensexs 5.41% fall.

The large-cap company has equity capital of Rs 270.46 crore. Face value per share is Rs 270.46.

Tata Power Company (Tata Power) reported consolidated net profit of Rs 336 crore in Q2 September 2016, compared with net loss of Rs 96 crore in Q2 September 2015. Consolidated total income from operations declined 5.96% to Rs 7209 crore in Q2 September 2016 over Q2 September 2015, due to lower revenue at standalone level due to lower fuel cost & lower power purchase, lower million units (MUs) traded at Tata Power Trading Company (TPTCL).

The company reported a turnaround in bottom line in Q2 September 2016 vis-n++-vis corresponding previous quarter mainly due to lower mark-to-market (MTM) losses at Coastal Gujarat Power (CGPL) and better performance by key Indian subsidiaries and Indonesian coal mines.

Tata Powers CEO & Managing Director Anil Sardana said, the company has improved profitability and has maintained strong operational performance across all business verticals. The companys subsidiaries continue to perform well despite challenging circumstances. Management is confident that the companys strong growth trajectory will continue into the next quarter, Sardana said.

Tata Powers 100% subsidiaries viz. Bhira Investments nd Bhivpuri Investments (selling companies) had signed an agreement for sale and purchase of shares on 30 January 2014, to sell its 30% stake in PT Arutmin, Indonesia and associated trading and infrastructure companies for an aggregate consideration of $510 million. Consequent to certain closing adjustments to the sale consideration and other changes agreed between the parties, the selling companies have signed revised definitive agreements with PT Cakrawala Langit Sejahtera (PT CLS) a Bakrie group entity on 28 November 2016.

The sale consideration for PT Arutmin is now revised to $246.64 million from the earlier value of $390 million, pursuant to closing adjustments relating to certain prior period liabilities, which includes settlement of past claims with mining contractor, pursuant to a court order (about $80 million as companys share) and other statutory liabilities (about $50 million.). The consideration is expected to be received in a phased manner over next few years.

With regard to the infrastructure company PT Mitratama Perkasa (PTMP), in which PT Sumber Energi Andalan Tbk (Sumber) holds Tata Powers 30% equity; and Trust Energy Resources Pte, a 100% subsidiary of the company (Trust Energy) which holds Sumber, has entered into an agreement with Rwood Resources, a Bakrie Group Entity, for divestment of 94.61% stake in Sumber. The sale consideration for Infrastructure companies is now revised to $154.28 million from the earlier value of $120 million, pursuant to closing adjustments relating to prior period. The consideration is expected to be received in a phased manner over next few years.

Meanwhile, Tata Powers board decided to convene an extraordinary general meeting of the shareholders of the company on 26 December 2016, for considering and passing a resolution for removal of Cyrus P. Mistry as director of the company.

Tata Power is Indias largest integrated power company with a growing international presence. The company together with its subsidiaries and jointly controlled entities has an installed gross generation capacity of 10,477 megawatts (MW) and a presence in all the segments of the power sector viz. fuel security and logistics, generation, transmission, distribution and trading.

Powered by Capital Market - Live News

JHS Svendgaard declines as Tano Mauritius liquidates bulk shares
Nov 29,2016

Meanwhile, the S&P BSE Sensex was up 39.12 points or 0.15% at 26,389.29.

On the BSE, 98,000 shares were traded on the counter so far as against average daily volumes of 78,744 shares in the past one quarter. The stock had hit a high of Rs 41.30 and a low of Rs 37 so far during the day. The stock had hit a 52-week low of Rs 12.71 on 20 December 2015. The stock had hit a 52-week high of Rs 46.30 on 1 November 2016. The stock had outperformed the market over the past one month till 28 November 2016, declining 4.24% compared with the Sensexs 5.7% fall. The scrip had also outperformed the market in past one quarter, advancing 12.06% as against the Sensexs 5.15% fall.

The small-cap company has equity capital of Rs 39.87 crore. Face value per share is Rs 10.

Tano Mauritius India FVCI owned 6.65% stake in JHS Svendgaard Laboratories end September 2016.

On a consolidated basis, JHS Svendgaard Laboratories reported net profit of Rs 1.35 crore in Q2 September 2016, compared with net loss of Rs 0.92 crore in Q2 September 2015. Net sales rose 20.7% to Rs 30.65 crore in Q2 September 2016 over Q2 September 2015.

JHS Svendgaard Laboratories is engaged in exporting, importing, trading, buying and selling of oral care/hygiene products (including toothbrushes and toothpastes).

Powered by Capital Market - Live News

Cadila Healthcare corrects on profit booking
Nov 29,2016

Meanwhile, the BSE Sensex was up 132.61 points, or 0.50%, to 26,482.78.

On BSE, so far 24,000 shares were traded in the counter, compared with average daily volume of 70,800 shares in the past one quarter. The stock hit a high of Rs 414.60 and a low of Rs 399.10 so far during the day. The stock hit a 52-week high of Rs 429.45 on 1 November 2016. The stock hit a 52-week low of Rs 295.50 on 18 January 2016. The stock had outperformed the market over the past 30 days till 28 November 2016, falling 1.86% compared with the 5.66% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 6.50% as against Sensexs 7.03% decline.

The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Re 1.

Shares of Cadila Healthcare rose 12.51% in five trading sessions to settle at Rs 411 yesterday, 28 November 2016, from its close of Rs 365.30 on 21 November 2016.

Cadila Healthcares consolidated net profit fell 28.93% to Rs 337.60 crore on 3.08% increase in net sales to Rs 2336.30 crore in Q2 September 2016 over Q2 September 2015.

Cadila Healthcare is a global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies.

Powered by Capital Market - Live News

Rally in Sagar Cements fizzles out on profit booking
Nov 29,2016

Meanwhile, the S&P BSE Sensex was up 114.82 points or 0.44% at 26,464.99.

On the BSE, 8,271 shares were traded on the counter so far as against the average daily volumes of 4,956 shares in the past one quarter. The stock had hit a high of Rs 724 and a low of Rs 692.45 so far during the day. The stock had hit a record high of Rs 835 on 14 October 2016. The stock had hit a 52-week low of Rs 350 on 18 February 2016. The stock had outperformed the market over the past one month till 28 November 2016, sliding 2.02% compared with the Sensexs 5.7% fall. The scrip had also outperformed the market in past one quarter, advancing 9.82% as against the Sensexs 5.15% fall.

The small-cap company has equity capital of Rs 17.39 crore. Face value per share is Rs 10.

Shares of Sagar Cements rallied 20.5% in the preceding five trading sessions to settle at Rs 714.05 yesterday, 28 November 2016, from its close of Rs 592.80 on 21 November 2016. Lions part of the rally materialized in a single trading session yesterday, 28 November 2016, when the stock settled higher by 15.19%, after the companys board at a meeting held on 28 November 2016, fixed an issue price of Rs 800 per equity share for the proposed issue of 6.11 lakh equity shares of the company on preferential basis, subject to requisite approvals. The issue price is at a premium of 15.04% over ruling market price.

Net profit of Sagar Cements declined 71.53% to Rs 2.50 crore on 29% decline in net sales to Rs 119.20 crore in Q2 September 2016 over Q2 September 2015.

Sagar Cements is engaged in manufacturing of cement.

Powered by Capital Market - Live News

Idea Cellular surges on buzz over stake sale in tower subsidiary
Nov 29,2016

Meanwhile, the S&P BSE Sensex was up 168.84 points or 0.64% at 26,519.01.

On the BSE, 9.43 lakh shares were traded on the counter so far as against average daily volumes of 10.01 lakh shares in the past one quarter. The stock had hit a high of Rs 79.55 and a low of Rs 77.60 so far during the day. The stock had hit a 52-week high of Rs 147.70 on 27 November 2015. The stock had hit a 52-week low of Rs 66 on 9 November 2016. The stock had outperformed the market over the past one month till 28 November 2016, sliding 0.52% compared with the Sensexs 5.7% fall. The scrip had, however, underperformed the market in past one quarter, declining 19.32% as against the Sensexs 5.15% fall.

The large-cap company has equity capital of Rs 3601.13 crore. Face value per share is Rs 10.

Idea Cellular has dropped its earlier plans to sell a minority stake in the tower business and now it is looking to sell 11,000 telecom towers for close to $1 billion, reports suggested.

On a consolidated basis, Idea Cellulars net profit fell 88% to Rs 91.46 crore on 7.2% growth in net sales to Rs 9298.89 crore in Q2 September 2016 over Q2 September 2015.

Idea Cellular is the third largest wireless operator in India. Idea is part of the Aditya Birla Group, which is one of the largest business groups in India.

Powered by Capital Market - Live News

Oil India slips over 4% in two sessions
Nov 29,2016

The result was announced during trading hours yesterday, 28 November 2016. Shares of Oil India fell 2.08% to Rs 427.80. The stock has fallen 4.30% in two trading sessions from its close of Rs 436.90 on 25 November 2016.

Meanwhile, the BSE Sensex was up 193.05 points, or 0.73%, to 26,543.22.

On BSE, so far 61,000 shares were traded in the counter, compared with average daily volume of 74,282 shares in the past one quarter. The stock hit a high of Rs 427.15 and a low of Rs 418.05 so far during the day. The stock hit a 52-week high of Rs 446 on 24 November 2016. The stock hit a 52-week low of Rs 300.50 on 1 March 2016. The stock had outperformed the market over the past 30 days till 28 November 2016, rising 2.58% compared with the 5.66% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 11.10% as against Sensexs 7.03% decline.

The large-cap company has equity capital of Rs 601.14 crore. Face value per share is Rs 10.

Oil Indias net profit of declined 17.8% to Rs 580.27 crore on 6.5% decline in net sales to Rs 2242.72 crore in Q2 September 2016 over Q2 September 2015.

Meanwhile, the company said in a separate announcement yesterday, 28 November 2016, that its board recommended issuing one bonus equity share for every three existing fully paid up equity share (1:3). The proposal is subject to approval of the shareholders.

The Government of India held 67.64% stake in Oil India as per the shareholding pattern as on 30 September 2016.

Powered by Capital Market - Live News

Volumes jump at Motilal Oswal Financial Services counter
Nov 29,2016

Motilal Oswal Financial Services clocked volume of 5.20 lakh shares by 13:24 IST on BSE, a 34.12-times surge over two-week average daily volume of 15,000 shares. The stock rose 3.05% to Rs 512.40.

PI Industries notched up volume of 2.04 lakh shares, a 8.62-fold surge over two-week average daily volume of 24,000 shares. The stock fell 0.68% to Rs 874.25.

Suven Life Sciences saw volume of 4.30 lakh shares, a 8.31-fold surge over two-week average daily volume of 52,000 shares. The stock rose 3.95% to Rs 181.40.

Reliance Industrial Infrastructure clocked volume of 2.07 lakh shares, a 5.08-fold surge over two-week average daily volume of 41,000 shares. The stock rose 10.58% to Rs 394.20.

TVS Electronics saw volume of 6.38 lakh shares, a 4.91-fold rise over two-week average daily volume of 1.30 lakh shares. The stock rose 10% to Rs 161.20.

Powered by Capital Market - Live News

Pfizer moves higher after undertaking review of its respiratory portfolio
Nov 29,2016

The announcement was made after market hours yesterday, 28 November 2016.

Meanwhile, the S&P BSE Sensex was up 200.17 points or 0.76% at 26,550.34.

On the BSE, 1,152 shares were traded on the counter so far as against the average daily volumes of 2,553 shares in the past one quarter. The stock had hit a high of Rs 1,850 and a low of Rs 1,818 so far during the day. The stock had hit a 52-week high of Rs 2,540 on 7 December 2015. The stock had hit a 52-week low of Rs 1,611 on 21 March 2016. The stock had outperformed the market over the past one month till 28 November 2016, sliding 0.64% compared with the Sensexs 5.7% fall. The scrip had, however, underperformed the market in past one quarter, declining 7.04% as against the Sensexs 5.15% fall.

The mid-cap company has equity capital of Rs 45.75 crore. Face value per share is Rs 10.

Pfizer has undertaken a comprehensive review of its respiratory offerings to better cover a broader range of indications through an expanded product portfolio. As a result of this review, the company will launch additional products while it may also discontinue the manufacture of certain SKUs where needed.

Pfizer will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 and subsequent launches over the next year.

The company has also decided to discontinue the manufacturing of the current Corex Cough Syrup formulation (Codeine Phosphate 10mg + Chlorpheniramine Maleate 4mg).

Pfizer said it stands by the safety and efficacy of its current Corex Cough Syrup formulation that has been duly approved by Central and state regulators. As with this formulation, all additional line extensions will be introduced with all due regulatory approvals in place, it added.

Corex Cough Syrup recorded a sale of Rs 244.48 crore for the financial year ended 31 March 2016.

Pfizers net profit rose 52.5% to Rs 126.33 crore on 4.9% growth in net sales to Rs 530.02 crore in Q2 September 2016 over Q2 September 2015.

Pfizer is a leading biopharmaceutical company.

Powered by Capital Market - Live News

Natco Pharma gains after USFDA approval for generic drug
Nov 29,2016

The announcement was made during trading hours today, 29 November 2016.

Meanwhile, the BSE Sensex was up 174.93 points, or 0.66%, to 26,525.10.

On BSE, so far 25,000 shares were traded in the counter, compared with average daily volume of 30,786 shares in the past one quarter. The stock hit a high of Rs 626 and a low of Rs 612.40 so far during the day. The stock hit a record high of Rs 703.95 on 25 August 2016. The stock hit a 52-week low of Rs 390 on 29 March 2016. The stock had outperformed the market over the past 30 days till 28 November 2016, rising 2.36% compared with the 5.66% decline in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 10.65% as against Sensexs 7.03% decline.

The large-cap company has equity capital of Rs 34.86 crore. Face value per share is Rs 2.

Natco Pharma announced receiving final approval of Abbreviated New Drug Application (ANDA) containing a paragraph IV certification filed with the US Food and Drug Administration (USFDA) for generic version of Armodafinil tablets, 50 milligrams (mg), 150 mg, and 250 mg. Natco and its marketing partner Breckenridge Pharmaceutical, Inc., plan to launch this product in the US market immediately.

Cephalon (acquired by Teva in 2011) sells Armodafinil 50mg, 150mg, and 250mg tablets under brand name NUVUGIL in the US market. NUVUGIL is a wakefulness promoting agent for oral administration. NUVUGIL Tablets had US sales of approximately $480 million for twelve months ending December 2015, according to IMS Health.

On a consolidated basis, net profit of Natco Pharma rose 127.21% to Rs 66.55 crore on 75.56% rise in net sales to Rs 415.21 crore in Q2 September 2016 over Q2 September 2015.

Natco Pharma manufactures generic dosage forms, bulk actives and intermediates for the Indian and international markets.

Powered by Capital Market - Live News